Modern drug discovery technologies: Opportunities and challenges in lead discovery

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 10, 2011, Pages 830-839

  Guido, Rafael V C ^a   Oliva, Glaucius ^a   Andricopulo, Adriano D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Drug discovery; High throughput screening; Lead discovery; Ligand based drug design; Virtual screening

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; BICUCULLINE; DOCETAXEL; ESOMEPRAZOLE; OMEPRAZOLE; PACLITAXEL; SILDENAFIL; ZOLPIDEM; ZOPICLONE;

ARTICLE; BREAST CARCINOMA; COMBINATORIAL CHEMISTRY; DRUG SCREENING; ERECTILE DYSFUNCTION; FEASIBILITY STUDY; HIGH THROUGHPUT SCREENING; OVARY CARCINOMA; PRIORITY JOURNAL; PROCESS MODEL; PULMONARY HYPERTENSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TECHNOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054923170     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620711797537067     Document Type: Article

References (57)

1. Andricopulo, A. D.; Salum, L. B.; Abraham, D. J. Structure-based drug design strategies in medicinal chemistry. Curr. Top. Med. Chem., 2009, 9, 771-790.
2. Guido, R. V. C.; Oliva, G.; Andricopulo, A. D. Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem., 2008, 15, 37-46. (Pubitemid 351234626)
3. Guido, R. V. C.; Oliva, G. Structure-based drug design for tropical diseases. Curr. Top. Med. Chem., 2009, 9, 824-843.
4. Salum, L. B.; Andricopulo, A. D. Fragment-based QSAR: perspectives in drug design. Mol. Divers., 2009, 13, 277-285.
5. Salum, L. B.; Andricopulo, A. D. Fragment-based QSAR strategies in drug discovery. Exp. Opin. Drug Discov., 2009, 5, 405-412.
6. Salum, L. B.; Dias, L. C.; Andricopulo, A. D. Fragment-based QSAR and molecular modeling studies on a series of discodermolide analogs as microtubule-stabilizing anticancer agents. QSAR Comb. Sci., 2009, 28, 325-337.
7. Honorio, K. M.; Garratt, R. C.; Polikatpov, I.; Andricopulo, A. D. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. J. Mol. Graph. Modell., 2007, 921-927. (Pubitemid 46223544)
8. Salum, L. B.; Polikarpov, I.; Andricopulo, A. D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. J. Chem. Inf. Model., 2008, 48, 2243-2253.
9. Moda, T. L.; Torres, L. G.; Carrara, A. E.; Andricopulo, A. D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics, 2008, 24, 2270-2271.
10. Moda, T. L.; Montanari, C. A.; Andricopulo, A. D. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg. Med. Chem., 2007, 15, 7738-7745. (Pubitemid 47575914)
11. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477. (Pubitemid 46595760)
12. Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol., 2008, 12, 306-317.
13. Chapman, A. D. Numbers of Living Species in Australia and the World. 2nd ed.; Canberra: Australia, 2009.
14. Benko-Iseppon, A. M.; Galdino, S. L.; Calsa, T., Jr.; Kido, E. A.; Tossi, A.; Belarmino, L. C.; Crovella, S. Overview on plant antimicrobial peptides. Curr. Protein Pept. Sci., 2010, 11, 181-188.
15. Kingston, D. G. The shape of things to come: structural and synthetic studies of taxol and related compounds. Phytochemistry, 2007, 68, 1844-1854. (Pubitemid 47030611)
16. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93, 2325-2327.
17. Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.; Renaud, J.; Couladouros, E. A.; Paulvannan, K. Total synthesis of taxol. Nature, 1994, 367, 630-634. (Pubitemid 24069071)
18. Roberts, S. C. Production and engineering of terpenoids in plant cell culture. Nat. Chem. Biol., 2007, 3, 387-395. (Pubitemid 46956326)
19. Ajikumar, P. K.; Xiao, W. H.; Tyo, K. E.; Wang, Y.; Simeon, F.; Leonard, E.; Mucha, O.; Phon, T. H.; Pfeifer, B.; Stephanopoulos, G. Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science, 2010, 330, 70-74.
20. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26. (Pubitemid 33653411)
21. Wermuth, C. G. Similarity in drugs: reflections on analogue design. Drug Discov. Today, 2006, 11, 348-354.
22. Andersson, T. Single-isomer drugs: true therapeutic advances. Clin. Pharmacokinet., 2004, 43, 279-285. (Pubitemid 38534751)
23. Ghofrani, H. A.; Osterloh, I. H.; Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov., 2006, 5, 689-702. (Pubitemid 44151606)
24. Wermuth, C. G.; Bourguignon, J. J.; Schlewer, G.; Gies, J. P.; Schoenfelder, A.; Melikian, A.; Bouchet, M. J.; Chantreux, D.; Molimard, J. C.; Heaulme, M.; et al. Synthesis and structureactivity relationships of a series of aminopyridazine derivatives of gamma-aminobutyric acid acting as selective GABA-A antagonists. J. Med. Chem., 1987, 30, 239-249. (Pubitemid 17003793)
25. Doble, A.; Canton, T.; Piot, O.; Zundel, J. L.; Stutzmann, J. M.; Cotrel, C.; Blanchard, J. C. The pharmacology of cyclopyrrolone derivatives acting at the GABAA/benzodiazepine receptor. Adv. Biochem. Psychopharmacol., 1992, 47, 407-418.
26. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res., 1991, 37, 287-371.
27. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem., 2005, 12, 23-49. (Pubitemid 40089827)
28. Zhao, H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov. Today, 2007, 12, 149-155. (Pubitemid 46188408)
29. Edwards, P. J. Current parallel chemistry principles and practice: application to the discovery of biologically active molecules. Curr. Opin. Drug Discov. Devel., 2009, 12, 899-914.
30. Sanchez-Martin, R. M.; Mittoo, S.; Bradley, M. The impact of combinatorial methodologies on medicinal chemistry. Curr. Top. Med. Chem., 2004, 4, 653-669. (Pubitemid 38849364)
31. Macarron, R. Critical review of the role of HTS in drug discovery. Drug Discov. Today, 2006, 11, 277-279.
32. Silverman, L.; Campbell, R.; Broach, J. R. New assay technologies for high-throughput screening. Curr. Opin. Chem. Biol., 1998, 2, 397-403. (Pubitemid 128423245)
33. Mayr, L. M.; Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol., 2009, 9, 580-588.
34. Frearson, J. A.; Collie, I. T. HTS and hit finding in academia-from chemical genomics to drug discovery. Drug Discov. Today, 2009, 14, 1150-1158.
35. Mascarello, A.; Chiaradia, L. D.; Vernal, J.; Villarino, A.; Guido, R. V. C.; Perizzolo, P.; Poirier, V.; Wong, D.; Martins, P. G.; Nunes, R. J.; Yunes, R. A.; Andricopulo, A. D.; Av-Gay, Y.; Terenzi, H. Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: kinetics, molecular modeling, toxicity and effect on growth. Bioorg. Med. Chem., 2010, 18, 3783-3789.
36. Chen, L.; Zhou, B.; Zhang, S.; Wu, L.; Wang, Y.; G., F. S.; Zhang, Z. Y. Identification and characterization of novel inhibitors of mPtpB, an essential virulent phosphatase from Mycobacterium tuberculosis. ACS Med. Chem. Lett., 2010, 1, 355-359.
37. Schneider, G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov., 2010, 9, 273-276.
38. Klebe, G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today, 2006, 11, 580-594.
39. Postigo, M. P.; Guido, R. V. C.; Oliva, G.; Castilho, M. S.; Pitta, I. R.; Albuquerque, J. F.; Andricopulo, A. D. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J. Chem. Inf. Model., 2010, 50, 1693-1705.
40. Castilho, M. S.; Postigo, M. P.; Pereira, H. M.; Oliva, G.; Andricopulo, A. D. Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni. Bioorg. Med. Chem., 2010, 18, 1421-1427.
41. Castilho, M. S.; Postigo, M. P.; Paula, C. B. V.; Montanari, C. A.; Oliva, G.; Andricopulo, A. D. Two- and three dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorg. Med. Chem., 2006, 14, 516-527. (Pubitemid 41767612)
42. Andricopulo, A. D.; Yunes, R. A. Structure-activity relationships for a collection of structurally diverse inhibitors of purine nucleoside phosphorylase. Chem. Pharm. Bull., 2001, 49, 10-17. (Pubitemid 32128088)
43. Carr, R. A.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragmentbased lead discovery: leads by design. Drug Discov. Today, 2005, 10, 987-992. (Pubitemid 40967047)
44. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragmentbased lead discovery. Nat. Rev. Drug Discov., 2004, 3, 660-672.
45. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431. (Pubitemid 38510559)
46. Murray, C. W.; Rees, D. C., The rise of fragment-based drug discovery Nat. Chem., 2009, 1, 187-192.
47. Manly, C. J.; Chandrasekhar, J.; Ochterski, J. W.; Hammer, J. D.; Warfield, B. B. Strategies and tactics for optimizing the hit-to-lead process and beyond-a computational chemistry perspective. Drug Discov. Today, 2008, 13, 99-109.
48. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 2007, 6, 211-219. (Pubitemid 46344625)
49. Murray, C. W.; Blundell, T. L. Structural biology in fragmentbased drug design. Curr. Opin. Struct. Biol., 2010, 20, 497-507.
50. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274, 1531-1534. (Pubitemid 26403929)
51. Hajduk, P. J. SAR by NMR: putting the pieces together. Mol. Interv., 2006, 6, 266-272. (Pubitemid 44556047)
52. Fischer, M.; Hubbard, R. E., Fragment-based ligand discovery. Mol. Interv., 2009, 9, 22-30.
53. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci., 2001, 41, 1308-1315.
54. Oprea, T. I. Current trends in lead discovery: are we looking for the appropriate properties? J. Comput. Aided Mol. Des., 2002, 16, 325-334. (Pubitemid 35414666)
55. Oprea, T. I.; Allu, T. K.; Fara, D. C.; Rad, R. F.; Ostopovici, L.; Bologa, C. G., Lead-like, drug-like or "pub-like": how different are they? J. Comput. Aided Mol. Des., 2007, 21, 113-119. (Pubitemid 46416670)
56. Murray, C. W.; Carr, M. G.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S.; Coyle, J. E.; Downham, R.; Figueroa, E.; Frederickson, M.; Graham, B.; McMenamin, R.; O'Brien, M. A.; Patel, S.; Phillips, T. R.; Williams, G.; Woodhead, A. J.; Woolford, A. J. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem., 2010, 53, 5942-5955.
57. Woodhead, A. J.; Angove, H.; Carr, M. G.; Chessari, G.; Congreve, M.; Coyle, J. E.; Cosme, J.; Graham, B.; Day, P. J.; Downham, R.; Fazal, L.; Feltell, R.; Figueroa, E.; Frederickson, M.; Lewis, J.; McMenamin, R.; Murray, C. W.; O'Brien, M. A.; Parra, L.; Patel, S.; Phillips, T.; Rees, D. C.; Rich, S.; Smith, D. M.; Trewartha, G.; Vinkovic, M.; Williams, B.; Woolford, A. J. Discovery of (2,4- dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1- ylmethyl)- 1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem., 2010, 53, 5956-5969.